Zivo Bioscience, Inc. (ZIVO): Nasdaq/NYSE listing notice — Zivo Bioscience granted Nasdaq extension to Nov 20, 2023 to regain equity compliance

Zivo Bioscience, Inc.

Received deficiency notice on May 23, 2023 for stockholders' equity below $2.5M (Listing Rule 5550(b)).
Nasdaq Hearings Panel held on July 13, 2023; extension granted until November 20, 2023.
Extension conditioned on filing Form S-1 with SEC by October 5, 2023.
Company intends to regain compliance but delisting risk remains; potential adverse effect on capital access.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Zivo Bioscience, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

August 4, 2023, the Company received a notification letter from the Nasdaq notifying the Company that the Panel has granted the Company’s request to provide an extension until November 20, 2023 (the “Exception Period”), to regain compliance with the Stockholders’ Equity Rule for continued listing on Nasdaq. The Panel further noted that the Exception Period for continued listing is subject to a filing of a registration statement on Form S-1 by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on or before October 5, 2023. The Panel concluded that the Exception Period is

View on SEC.gov

Browse all listing & compliance notices →

Zivo Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-010378

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.